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Abstract 
Measles is one of the most deadly vaccine 
preventable diseases. The incidence of measles, and 
resultant mortality, had dropped drastically 
following the introduction of widespread measles 
immunisation since the 1960s. However, there is 
currently a worldwide surge in measles cases, with 
a marked increase over the past 3 years. Measles 
outbreaks and endemic transmission have been re-
established in countries which had previously 
achieved measles elimination. The rise in measles 
cases has been mainly attributed to a drop in the 
recommended two dose vaccination schedule below 
the 95% uptake threshold necessary for interruption 
of transmission and sustainment of herd protection. 
This resurgence of measles is largely a result of the 
damage done by Andrew Wakefield, who in 1998 
incorrectly and maliciously suggested a possible 
link between the measles, mumps and rubella 
(MMR) vaccine and autism. Such a possible 
association has subsequently been disproven by 
several scientifically robust studies. Still, most 
cases of measles have occurred in unimmunised 
individuals, mainly teenagers, who had missed out 
on vaccination in early childhood, and in infants 
under one year of age, who are too young to be 
vaccinated. Measles is highly contagious, with up to 
18 people being potentially infected from a single 
case, so containment measures are important to 
prevent spread. These include isolation and 
immediate notification of suspected or confirmed 
cases, as well as wearing appropriate personal 
protective equipment when in contact with these 
patients. Health care professionals have a crucial 
role in promoting measles immunisation, which is 
the only rational way of preventing measles. 
 
 
 
 
 
 
 
 
 
Measles is one of the most deadly vaccine-
preventable diseases1 and is included in the top 
overall causes of death in children under 5 years of 
age worldwide.2  
Prior to the introduction of widespread 
measles vaccination in 1963, measles accounted for 
about 2.6 million deaths annually.3 In fact, one of 
the aims of the Global Vaccine Action Plan 2011 – 
20204 was the elimination of measles in 4 out of 5 
World Health Organization (WHO) regions by 
2015, but this aim has not been achieved.5 Measles 
elimination is defined as the absence of endemic 
measles virus transmission in a region or other 
defined geographic area for ≥12 months, in the 
presence of a high quality surveillance system that 
meets targets of key performance indicators.6  
In theory, eradication of measles is possible 
because humans are the only reservoirs,7 measles is 
only infectious during the acute phase,7 specific and 
rapid diagnostic tests are available,8 the measles 
virus is monotypic8 and a monovalent vaccine is 
effective against all known virus isolates.8  
The measles virus is aerosol-borne and is 
easily spread by coughing and sneezing, close 
personal contact or direct contact with infected 
nasal or throat secretions.3 Measles is highly 
contagious, starting from four days prior onset of 
the rash until four days following rash appearance.1 
Over 90% of contacts develop the disease.9 The 
basic reproduction number (R0) for measles lies 
between 12 and 18,10 meaning that a single patient 
with measles may infect up to 18 susceptible 
people.9 In comparison, R0 for influenza is 
estimated between 2 and 411 while R0 for varicella 
ranges between 3.7 and 5.12  
The clinical description for measles by the 
Centers for Disease Control and Prevention (CDC) 
states that measles is an acute illness characterised 
by a generalised maculopapular rash that is present 
for at least 3 days, an oral temperature of at least 
101 ̊F (38.3 ̊C) and the presence of cough, coryza, 
and conjunctivitis.13 The pathognomonic Koplik 
spots on the buccal mucosa, which are not always 
present, are not a diagnostic criterion.7 The 
incubation period for measles is 10 days for onset 
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of fever; the rash usually appears 4 days later.7 
Laboratory diagnosis, which is a requisite for case 
confirmation, may be performed by detecting 
measles IgM in serum or saliva.14 Of note, 30% 
may be negative in the initial 3 days and the tests 
should not be performed later than 4 weeks from 
onset of the rash.15 False positives may occur 
especially with rubella and parvovirus B19 
infections.16 PCR testing on respiratory secretions, 
nasopharyngeal swab, blood or urine may be 
needed for genetic characterisation of the virus, 
which can help identify the source of infection.17 
There is no specific treatment for measles.  
 Measles complications can occur in up to 40% 
of patients and are more common in high-risk 
patients.7 Pneumonia occurs in up to 1 in 16 
patients18 and is the leading cause of measles-
associated death.1 Other complications include otitis 
media (in about 1 in 12 measles cases)18, diarrhoea 
(in about 1 in 12 measles cases),18 ocular 
complications and central nervous system 
manifestations, such as encephalitis (in about 1 in 
every 1000 - 2000 measles cases)18 or subacute 
sclerosing panencephalitis (in about 4 - 11 per 
100,000 measles cases).1 Measles also causes long-
lasting memory B and T cell impairment.19 High-
risk patients include immunosuppressed patients (in 
whom typical signs and symptoms may be absent), 
patients with Vitamin A deficiency, malnourished 
patients and travellers.7 Young infants also have a 
higher risk of mortality and complications,7 
especially if born to mothers with vaccine-derived 
immunity or who are infected with HIV.20 Passive 
immunity lasts longer in mothers with natural 
immunity to measles but by 6 months of age less 
than 5% of all infants retain maternal antibodies.21 
A proportion of individuals with measles will 
need hospital admission. Unfortunately, hospital 
admission is associated with measles 
transmission,22 including outbreaks amongst 
healthcare workers.23 The cost of delay in diagnosis 
and the resultant potential exposure is prohibitive, 
in view of the high infectivity of measles.24 Patients 
suspected of having measles should be isolated 
immediately and measures should be in place to 
prevent further spread during outbreaks. The virus 
remains infective for two hours on solid surfaces, 
which should be borne in mind when 
decontaminating a room.25 Infection control 
measures should be implemented as per local 
recommendations and respiratory protection by 
means of N95 or FFP3 (filtering facepiece class 3) 
mask should be worn when attending to a patient 
with suspected or confirmed measles,26 irrespective 
of the immunity of the healthcare worker to 
measles. A normal surgical mask should be worn if 
a FFP is not available – this will still provide a 
reasonable level of protection.27  
The only rational way of preventing measles 
in a population is through vaccination. The MMR 
(measles, mumps, rubella) vaccine has 99% 
effectiveness against measles following 2 doses,28 is 
well tolerated, safe,29 and offers long-lasting 
protection.30 In fact, measles vaccination is 
estimated to have prevented 20.4 million deaths 
between 2000 – 2016.31 However, in view of the 
high R0 for measles, a high uptake of at least 95% 
for both doses is needed in order to eliminate 
measles from a population and to attain herd 
protection.32-33  
In Malta, the first dose of MMR vaccine is 
administered at 13 months of age, with the second 
dose being given at 3 to 4 years of age.34 This is in 
line with the WHO recommendations that two 
doses of measles-containing vaccine, such as the 
MMR vaccine, for countries with low risk of 
measles should be given at around 12 months of age 
for the first dose and that the second dose of MMR 
vaccine should be given at the age when maximum 
coverage at national level is anticipated.35 A 
supplementary dose of measles vaccine is 
recommended from 6 months of age onwards 
during measles outbreaks35. Any dose of measles 
vaccine given before 12 months of age should not 
be counted as part of the series and these children 
should be revaccinated with 2 doses of the MMR 
vaccine after 12 months of age.36 
Unfortunately, measles immunisation rates 
have dropped globally. During 2017, 85% of 
children received one dose of measles vaccine by 
their second birthday, with only 67% receiving the 
second dose as part of routine immunisation.37 In 
Europe, immunisation rates for 2017 were 95% for 
the first dose and 90% for the second dose.38 The 
single most influential factor for the drop in measles 
vaccine uptake was an article by Dr Andrew 
Wakefield in The Lancet in 1998,39 which 
suggested a potential link between the MMR 
vaccine and developmental regression and autism, 
among other conditions. This paper received 
disproportionate media coverage and caused the 
biggest public health scare in UK history.40 Flaws 
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in research methods were immediately pointed out, 
including that it was a case series of 12 children 
without controls and that data collection relied on 
parent’s personal beliefs and recalls.41 Large 
epidemiological studies over the years,42-46 as well 
as a WHO extensive review47 and a Cochrane 
systematic review,48 have since disproved any links 
between the MMR vaccine and autism. The UK 
General Medical Council found that Dr Wakefield 
had falsified his data and had breached ethical 
standards in this publication49 and consequently he 
was struck off the register because of his serious 
professional misconduct.50 The paper was also 
withdrawn by The Lancet in 2010.51 However, it is 
still widely quoted by anti-vaccine campaigners and 
parents, some of whom remain unsure whom to 
believe, despite all the robust scientific evidence 
proving that the MMR vaccine is not associated 
with autism.52  
Endemic transmission of measles can be re-
established once vaccination rates fall below the 
elimination threshold.53 In fact, measles has again 
become endemic in all five WHO regions during 
2018, with the rate of measles being the highest in a 
decade54 and continuing to rise by a further 300% 
during the first quarter of 2019.55 Over 82,000 
people in the WHO European region contracted 
measles during 2018, with up to 61% needing 
hospitalisation and 72 deaths in children and 
adults.38 This is more than three times as many as in 
2017, 15 times as many as in 201618 and even 
surpassed the number of measles cases in the WHO 
African region in 2018, which totalled 33,879.56 
This figure includes national outbreaks in countries 
having previously achieved measles elimination, 
such as The Netherlands57 and Greece,58 and also 
the re-establishment of endemic transmission in 
countries where measles had been eliminated, as 
happened in the United Kingdom.59  
Malta has maintained the status of measles 
elimination in 2018, because there have not been 
any cases of measles due to sustained 
transmission.60 However, there is an increasing 
trend in locally acquired measles, rising from 6 
cases in 201860 to 15 confirmed cases so by April 
2019 - 23 cases in adults and 2 cases in children.61 
During 2018, 95.5% of children in Malta received 
the first dose of MMR and 95% received the second 
dose of MMR vaccine.62 This is in contrast to 
previous years, when immunisation rates in Malta 
had dropped below the 95% uptake rate (for both 
doses) needed to prevent disease transmission. In 
fact, only 91% of children received the first dose of 
MMR vaccine and 83% received the second dose 
during 201763, although this could be a result of 
inadequate notification. This is the ideal scenario 
for breakthrough cases of measles and, in the 
absence of herd protection, the potential for 
outbreaks, as has happened in other countries.  
Indeed, the surge in measles in Europe has 
been mainly attributed to a drop in two-dose 
measles vaccine coverage below 95% and a drop in 
prevalence of individuals with vaccine-induced 
protection of measles to less than 94.4%.64 Out of 
the 14,400 reported cases of measles in Europe in 
201765 with known vaccination status, 87% were 
unimmunised, 8% had received one dose of 
measles-containing vaccine, 3% had received two 
or more doses of vaccine and 2% were vaccinated 
with an unknown number of doses.66 Immunisation 
status was unknown for 6%.66 Thirty seven percent 
of measles occurred in children under 5 years of 
age, with the highest disease burden occurring in 
children below the age of 1 year, while 45% 
occurred in patients older that fifteen years.66 
Therefore, nearly half of the measles cases in 
Europe occurred in unimmunised adolescents aged 
15 years or older, highlighting the need to identify 
and catch-up those who missed out on routine 
vaccination in childhood.  
 The resurgence of measles at a global level is 
being driven by multiple factors, including conflict, 
poor health education, lack of access to health care, 
complacency, increasing vaccine hesitancy and low 
support amongst medical personnel.67 In addition, 
vaccine coverage may be suboptimal in at-risk 
groups, including Roma, Irish travellers, orthodox 
religious communities67 and adolescent and adult 
migrants, who might be excluded from the 
immunisation catch-up initiatives provided to 
younger children.68 Failure to address vaccination 
shortfalls in vulnerable populations will create 
immunisation gaps and lead to subnational 
coverage.  
Measles is a vaccine-preventable disease 
which carries a high morbidity and mortality. 
Elimination of measles is dependent on sustaining 
herd protection and in limiting transmission during 
outbreaks. Our role as health care professionals is to 
actively encourage MMR vaccine uptake, including 
opportunistic vaccination for those who were not 
immunised at the appropriate times, address public 
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concerns, expedite the diagnosis of measles, notify 
immediately any suspected or confirmed cases and 
help in containing outbreaks.  
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